Literature DB >> 27354907

Ketamine enantiomers in the rapid and sustained antidepressant effects.

John Muller1, Sahana Pentyala1, James Dilger1, Srinivas Pentyala2.   

Abstract

Recent evidence has suggested that the N-methyl-D-aspartate receptor antagonist ketamine shows significant therapeutic effects in major depression and bipolar disorder. This effect is especially important in treatment-resistant depression and depression with suicidal ideation. In this review we explain the mechanism of action, drug efficacy, and the side effects of ketamine; the antidepressive effects of ketamine; the individual effects of ketamine isomers, R(-) ketamine and S(+) ketamine; the effects of the combination of ketamine with electroconvulsive therapy; and the possible use of ketamine in treating depression.

Entities:  

Keywords:  depression; electroconvulsive therapy; ketamine

Year:  2016        PMID: 27354907      PMCID: PMC4910398          DOI: 10.1177/2045125316631267

Source DB:  PubMed          Journal:  Ther Adv Psychopharmacol        ISSN: 2045-1253


  38 in total

1.  Pharmacology of ketamine isomers in surgical patients.

Authors:  P F White; J Ham; W L Way; A J Trevor
Journal:  Anesthesiology       Date:  1980-03       Impact factor: 7.892

Review 2.  [S-(+)-ketamine. Circulatory interactions during total intravenous anesthesia and analgesia-sedation].

Authors:  H A Adams
Journal:  Anaesthesist       Date:  1997-12       Impact factor: 1.041

Review 3.  Pro- and anticonvulsant effects of anesthetics (Part II)

Authors:  P A Modica; R Tempelhoff; P F White
Journal:  Anesth Analg       Date:  1990-04       Impact factor: 5.108

4.  Tissue uptake of ketamine and norketamine enantiomers in the rat: indirect evidence for extrahepatic metabolic inversion.

Authors:  S R Edwards; L E Mather
Journal:  Life Sci       Date:  2001-09-14       Impact factor: 5.037

5.  Ketamine and MK-801 decrease acetylcholine release in the pontine reticular formation, slow breathing, and disrupt sleep.

Authors:  Ralph Lydic; Helen A Baghdoyan
Journal:  Sleep       Date:  2002-09-15       Impact factor: 5.849

6.  Rapid antidepressant effect of ketamine anesthesia during electroconvulsive therapy of treatment-resistant depression: comparing ketamine and propofol anesthesia.

Authors:  Nagahisa Okamoto; Tetsuji Nakai; Kota Sakamoto; Yuko Nagafusa; Teruhiko Higuchi; Toru Nishikawa
Journal:  J ECT       Date:  2010-09       Impact factor: 3.635

7.  Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans.

Authors:  J A Clements; W S Nimmo; I S Grant
Journal:  J Pharm Sci       Date:  1982-05       Impact factor: 3.534

8.  Augmentation Therapy With Serial Intravenous Ketamine Over 18 Months in a Patient With Treatment Resistant Depression.

Authors:  Sameer Hassamal; Margaret Spivey; Ananda K Pandurangi
Journal:  Clin Neuropharmacol       Date:  2015 Sep-Oct       Impact factor: 1.592

9.  Ketamine, but not phencyclidine, selectively modulates cerebellar GABA(A) receptors containing alpha6 and delta subunits.

Authors:  Wulf Hevers; Stephen H Hadley; Hartmut Lüddens; Jahanshah Amin
Journal:  J Neurosci       Date:  2008-05-14       Impact factor: 6.167

10.  The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R).

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Doreen Koretz; Kathleen R Merikangas; A John Rush; Ellen E Walters; Philip S Wang
Journal:  JAMA       Date:  2003-06-18       Impact factor: 56.272

View more
  17 in total

Review 1.  Antidepressant Efficacy and Tolerability of Ketamine and Esketamine: A Critical Review.

Authors:  P Molero; J A Ramos-Quiroga; R Martin-Santos; E Calvo-Sánchez; L Gutiérrez-Rojas; J J Meana
Journal:  CNS Drugs       Date:  2018-05       Impact factor: 5.749

Review 2.  Engaging homeostatic plasticity to treat depression.

Authors:  E R Workman; F Niere; K F Raab-Graham
Journal:  Mol Psychiatry       Date:  2017-11-14       Impact factor: 15.992

Review 3.  Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.

Authors:  Dawn F Ionescu; Julia M Felicione; Aishwarya Gosai; Cristina Cusin; Philip Shin; Benjamin G Shapero; Thilo Deckersbach
Journal:  Harv Rev Psychiatry       Date:  2018 Nov/Dec       Impact factor: 3.732

Review 4.  Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism.

Authors:  Lily R Aleksandrova; Anthony G Phillips; Yu Tian Wang
Journal:  J Psychiatry Neurosci       Date:  2017-06       Impact factor: 6.186

Review 5.  Evaluating the Role of Ketamine/Esketamine in the Management of Major Depressive Disorder with Suicide Risk.

Authors:  Sina Nikayin; Gerard Sanacora
Journal:  CNS Drugs       Date:  2021-09-07       Impact factor: 5.749

6.  Right Frontal Theta: Is It a Response Biomarker for Ketamine's Therapeutic Action in Anxiety Disorders?

Authors:  Shabah M Shadli; Robert G Delany; Paul Glue; Neil McNaughton
Journal:  Front Neurosci       Date:  2022-07-04       Impact factor: 5.152

Review 7.  Role of Ketamine in the Treatment of Psychiatric Disorders.

Authors:  Sahar Derakhshanian; Maxine Zhou; Alexander Rath; Rachel Barlow; Sarah Bertrand; Caroline DeGraw; Christopher Lee; Jamal Hasoon; Alan D Kaye
Journal:  Health Psychol Res       Date:  2021-06-22

8.  Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers.

Authors:  Dmitriy Matveychuk; Rejish K Thomas; Jennifer Swainson; Atul Khullar; Mary-Anne MacKay; Glen B Baker; Serdar M Dursun
Journal:  Ther Adv Psychopharmacol       Date:  2020-05-11

Review 9.  Brain NMDA Receptors in Schizophrenia and Depression.

Authors:  Albert Adell
Journal:  Biomolecules       Date:  2020-06-23

Review 10.  Ketamine and Calcium Signaling-A Crosstalk for Neuronal Physiology and Pathology.

Authors:  Malwina Lisek; Ludmila Zylinska; Tomasz Boczek
Journal:  Int J Mol Sci       Date:  2020-11-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.